Bryce Point Capital, LLC Avidity Biosciences, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 14,044 shares of RNA stock, worth $447,020. This represents 0.12% of its overall portfolio holdings.
Number of Shares
14,044Holding current value
$447,020% of portfolio
0.12%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
252Shares Held
109MCall Options Held
197KPut Options Held
184K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$338 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$300 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$274 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$259 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$258 Million0.04% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.66B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...